204 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
9
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.
Takeda Pharmaceutical
5
Novel approach of fragment-based lead discovery applied to renin inhibitors.
Takeda Pharmaceutical
13
Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.
Takeda Pharmaceutical
44
Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin.
China Pharmaceutical University
45
trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.
Novartis Pharma
25
trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
Novartis Pharma
16
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.
Merck Research Laboratories
20
Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.
Novartis Institutes For Biomedical Research
18
Inhibitors ofß-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
Amgen
1
Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position.
Kyoto Pharmaceutical University
5
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations.
Novartis Institutes For Biomedical Research
19
Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.
Daiichi Sankyo
46
Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor.
Daiichi Sankyo
37
ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
F. Hoffmann-La Roche
9
The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
Novartis Pharma
9
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
Novartis Pharma
34
Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin.
Sanofi Recherche
7
An integrated computational workflow for efficient and quantitative modeling of renin inhibitors.
Sanofi Us
12
Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors.
Daiichi Sankyo
33
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
1
Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
National Hellenic Research Foundation
28
Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors.
Daiichi Sankyo
9
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
TBA
22
Design and synthesis of potent, isoxazole-containing renin inhibitors.
Merck Frosst Centre For Therapeutic Research
5
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
University of Florida
53
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Actelion Pharmaceuticals
19
Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.
E. Merck Darmstadt
50
Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.
Abbott Laboratories
31
Highly potent, orally active diester macrocyclic human renin inhibitors.
Merck Research Laboratories
13
Specific inhibition of HIV-1 protease by boronated porphyrins.
University of California
22
Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.
Parke-Davis Pharmaceutical Research Division of Warner-Lambert
44
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.
Warner-Lambert
7
Determination of dissociation constants of high affinity (pM) human renin inhibitors: application to analogues of ditekiren (U-71,038).
Upjohn Laboratories
14
Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.
Warner-Lambert
24
Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
Merck Sharp and Dohme Research Laboratories
30
Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites.
E. Merck Darmstadt
20
Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp.
Ici Pharmaceuticals Group
17
Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action.
Abbott Laboratories
14
Renin inhibitory peptides. A beta-aspartyl residue as a replacement for the histidyl residue at the P-2 site.
Upjohn
8
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
Kissei Pharmaceutical
20
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.
University of Wisconsin-Madison
15
Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.
Abbott Laboratories
7
Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Leu psi [CH2S]Val, or Leu psi [CH2SO]Val at the P1-P1' cleavage site.
Upjohn
5
Conformationally constrained renin inhibitory peptides: gamma-lactam-bridged dipeptide isostere as conformational restriction.
Upjohn
28
Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
Upjohn
19
Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.
TBA
7
alpha-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model.
TBA
35
Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.
Abbott Laboratories
13
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.
TBA
12
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.
TBA
15
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
TBA
7
Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.
TBA
4
Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid.
TBA
8
Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid.
TBA
15
Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension.
TBA
18
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties
TBA
13
3,4-Diarylpiperidines as potent renin inhibitors.
Merck Frosst Center For Therapeutic Research
13
Discovery of pyrrolidine-basedß-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.
Merck Research Laboratories
29
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.
Merck Frosst Centre For Therapeutic Research
43
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.
Merck Frosst Centre For Therapeutic Research
55
Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
Deutschland
43
Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
Sanofi-Aventis Deutschland
35
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.
Vitae Pharmaceuticals
19
Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin.
China Pharmaceutical University
35
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.
Merck Frosst Centre For Therapeutic Research
12
Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches.
Gyeongsang National University (Gnu)
20
The discovery and synthesis of potent zwitterionic inhibitors of renin.
Merck Frosst Centre For Therapeutic Research
67
Design and synthesis of aminohydantoins as potent and selective humanß-secretase (BACE1) inhibitors with enhanced brain permeability.
Pfizer
45
Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.
Sanofi-Aventis Deutschland
30
Piperidine-based renin inhibitors: upper chain optimization.
Actelion Pharmaceuticals
34
Design and optimization of new piperidines as renin inhibitors.
Actelion Pharmaceuticals
21
Identification of a new biaryl scaffold generating potent renin inhibitors.
Merck Frosst Center For Therapeutic Research
1
Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.
Merck Frosst Centre For Therapeutic Research
19
Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.
Merck Frosst Centre For Therapeutic Research
18
New classes of potent and bioavailable human renin inhibitors.
Actelion Pharmaceuticals
30
Optimization of orally bioavailable alkyl amine renin inhibitors.
Vitae Pharmaceuticals
48
Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.
Wyeth Research
28
Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.
Wyeth Research
7
Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
University of Toyama
18
The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.
Nagasaki International University
18
Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin
TBA
15
Novel low molecular renin inhibitors which show good oral blood pressure lowering effects in marmosets
TBA
16
Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small non-peptide renin inhibitors
TBA
3
Synthesis of α-hydroxy statine through a facially selective osmylation of a chiral α-amido crotonate
TBA
9
Rational design, synthesis, and X-ray structure of renin inhibitors with extended P1 sidechains
TBA
15
The identification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration.
TBA
6
Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites
TBA
6
MDL 74147, a novel selective and soluble inhibitor of human renin. Synthesis, structure-activity relationship, species and protease selectivities.
TBA
21
Conformationally restricted peptide isosteres. 2.1 Synthesis and in vitro potency of dipeptide renin inhibitors employing a 2-alkylsulfonyl-3-phenylcyclopropane carboxamide as a P3 amino acid replacement
TBA
2
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Abbott Laboratories
2
On-Resin Assembly of Macrocyclic Inhibitors of Cryptococcus neoformans May1: A Pathway to Potent Antifungal Agents.
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
4
An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
Tripura University
25
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Merck Research Laboratories
65
Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.
Vrije Universiteit Brussel
10
A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years.
University of Electronic Science and Technology of China
24
Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.
Mitsubishi Tanabe Pharma
18
Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.
Mitsubishi Tanabe Pharma
32
Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors.
Pfizer
15
Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors.
Merck
12
Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors.
Pfizer
73
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Kalvista Pharmaceuticals
6
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of
Ucb
1
Re-emerging Aspartic Protease Targets: Examining
Institute of Organic Chemistry and Biochemistry of The Czech Academy of Sciences
15
The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.
Pfizer
4
Rational design and synthesis of selective BACE-1 inhibitors.
Merck Research Laboratories
15
Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors.
Novartis Institutes For Biomedical Research
1
Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.
Annamalai University
20
Piperidine-renin inhibitors compounds with improved physicochemical properties.
F. Hoffmann-La Roche
26
Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site.
F. Hoffmann-La Roche
22
Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
TBA
22
Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-725
Abbott Laboratories
30
Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.
Abbott Laboratories
15
Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.
University of Florida
14
Analyses of ligand binding in five endothiapepsin crystal complexes and their use in the design and evaluation of novel renin inhibitors.
Warner-Lambert
54
Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.
Abbott Laboratories
8
Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin.
Boehringer Ingelheim Pharmaceuticals
9
Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effects of structure on inhibition of pepsin and renin.
TBA
5
Inhibition of renin by substrate analogue inhibitors containing the olefinic amino acid 5(S)-amino-7-methyl-3(E)-octenoic acid.
TBA
25
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.
TBA
33
Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.
Abbott Laboratories
12
Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini.
Merck Sharp & Dohme Research Laboratories
8
alpha,alpha-Difluoro-beta-aminodeoxystatine-containing renin inhibitory peptides.
Upjohn
21
Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond.
Abbott Laboratories
30
Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.
TBA
9
Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel. (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid.
TBA
16
New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.
Abbott Laboratories
7
Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen.
Abbott Laboratories
14
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability.
Abbott Laboratories
49
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.
Abbott Laboratories
11
Synthesis and biological activity of some transition-state inhibitors of human renin.
Ciba-Geigy
9
New human renin inhibitors containing an unnatural amino acid, norstatine.
Kissei Pharmaceutical
18
Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.
University of Wisconsin
19
Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency.
Merck Sharp & Dohme Research Laboratories
37
Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.
Glaxosmithkline
18
Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond.
Ciba-Geigy Pharmaceuticals Division
48
Renin inhibitors containing isosteric replacements of the amide bond connecting the P3 and P2 sites.
Warner-Lambert
19
Renin inhibitors based on dipeptide analogues. Incorporation of the hydroxyethylene isostere at the P2/P3 sites.
Abbott Laboratories
14
Inhibitors of human renin. Cyclic peptide analogues containing a D-Phe-Lys-D-Trp sequence.
Ici Pharmaceuticals Group
13
Thermodynamics of the interaction of inhibitors with the binding site of recombinant human renin.
Upjohn
21
Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.
Abbott Laboratories
25
Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.
Takeda Pharmaceutical
13
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives.
Ici Pharmaceuticals Group
15
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives.
Ici Pharmaceuticals Group
14
New inhibitors of renin that contain novel phosphostatine Leu-Val replacements.
Abbott Laboratories
32
Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations.
Bioleap
14
Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin infused rat model and in conscious sodium-depleted monkeys.
Upjohn
10
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 3.1 Synthesis and biological properties of aminodeoxystatine and difluorostatone derivatives.
Ici Pharmaceuticals Group
49
New inhibitors of human renin that contain novel replacements at the P2 site.
Warner-Lambert
8
Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors.
Merck Sharp and Dohme Research Laboratories
24
Renin inhibitors containing C-termini derived from mercaptoheterocycles.
Merck Sharp & Dohme Research Laboratories
44
C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.
Abbott Laboratories
35
Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement.
Abbott Laboratories
21
1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors.
University of Texas
33
Renin inhibitors containing alpha-heteroatom amino acids as P2 residues.
Warner-Lambert
10
Synthesis and use of 3-amino-4-phenyl-2-piperidones and 4-amino-2-benzazepin-3-ones as conformationally restricted phenylalanine isosteres in renin inhibitors.
Merck Sharp and Dohme Research Laboratories
12
New modified heterocyclic phenylalanine derivatives. Incorporation into potent inhibitors of human renin.
Wyeth-Ayerst Research
19
Inhibitors of human renin with C-termini derived from amides and esters of alpha-mercaptoalkanoic acids.
Merck Research Laboratories
30
Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'.
E. Merck Darmstadt
61
PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1
Thryv Therapeutics
1
Synthesis and preliminary biological assay of uridine glycoconjugate derivatives containing amide and/or 1,2,3-triazole linkers.
Silesian University of Technology
3
Modulation of [35S]TBPS binding by ligands with preferential affinity for benzodiazepine BZ1 sites in the cerebral cortex of newborn and adult rats.
University of Cagliari
18
Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8.
National Health Research Institutes
34
Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents.
Hoffmann-La Roche
20
Identification of selective inhibitors of cyclin dependent kinase 4.
Dupont Pharmaceuticals